RITALIN-SR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITALIN-SR is an extended-release oral tablet formulation of methylphenidate, a central nervous system stimulant. The mechanism of action involves inhibition of dopamine and norepinephrine reuptake, enhancing neurotransmitter availability in the brain. It is primarily indicated for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy in pediatric and adult populations.
LOE Approaching
With LOE approaching, the brand team is transitioning from growth to defensive strategy, likely reducing headcount and shifting focus to retention and lifecycle management initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers
Started May 2010
30 enrolled
Pharmacokinetics
Career Relevance
RITALIN-SR offers limited growth-oriented career opportunities given its LOE-approaching status; roles focus on defensive brand management, generic conversion, and retention strategy rather than expansion. Professionals seeking dynamic launch or growth-phase experience should consider emerging competitors; however, this product provides stability and deep therapeutic expertise in a foundational ADHD franchise.
Brand Manager
Worked on RITALIN-SR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.